Cell membrane receptors utilize numerous intracellular second messengers to propagate their signal into and through the cell. Individual receptors can activate many intracellular signaling pathways. An instrument capable of examining in real time either one specific signal pathway in detail or multiple pathways at the same time in a high throughput manner can be a valued asset to basic research. The Fluorometric Imaging Plate Reader (FLIPR 1) was originally designed to utilize fluorescent dyes to monitor changes in cell membrane potential. Subsequently the FLIPR1 was used to monitor rapid intracellular changes in calcium. The FLIPR1 has proven to be a valuable investigative tool for the investigators at the Medical University of South Carolina. Its age along with the lack of current support from the manufacturer has put the FLIPR1 in a condition bordering on obsolescence. The newest version of the FLIPR, FLIPRtetra, has expanded on the basic concepts of the original instrument. FLIPRtetra, features 96, 384 and 1536 well configurations, multi-wavelength kinetic readings, LED modules and user configurable excitation and emission filters, an optional adapter for addition of cell suspensions and enhanced luminescence sensitivity with the optional aequorin luminescence camera. With the user configurable LED excitation modules, the FLIPRtetra has expanded dye capabilities to include: ratiometric voltage sensing, mitochondrial membrane de-polarization, intracellular glutathione levels, reactive oxygen species and others. The FLIPRtetra will provide NIH-funded investigators a new tool to examine a myriad of intracellular signal systems and provide them with new information that will allow them to expand their research and knowledge.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Biomedical Research Support Shared Instrumentation Grants (S10)
Project #
1S10RR027777-01
Application #
7794548
Study Section
Special Emphasis Panel (ZRG1-BST-F (30))
Program Officer
Levy, Abraham
Project Start
2010-03-04
Project End
2011-03-03
Budget Start
2010-03-04
Budget End
2011-03-03
Support Year
1
Fiscal Year
2010
Total Cost
$499,800
Indirect Cost
Name
Medical University of South Carolina
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Luttrell, Louis M; Maudsley, Stuart; Gesty-Palmer, Diane (2018) Translating in vitro ligand bias into in vivo efficacy. Cell Signal 41:46-55
Lee, Mi-Hye; Appleton, Kathryn M; El-Shewy, Hesham M et al. (2017) S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization. J Lipid Res 58:325-338
Lee, Mi-Hye; Appleton, Kathryn M; Strungs, Erik G et al. (2016) The conformational signature of ?-arrestin2 predicts its trafficking and signalling functions. Nature 531:665-8
Wilson, Parker C; Fitzgibbon, Wayne R; Garrett, Sara M et al. (2015) Inhibition of Sphingosine Kinase 1 Ameliorates Angiotensin II-Induced Hypertension and Inhibits Transmembrane Calcium Entry via Store-Operated Calcium Channel. Mol Endocrinol 29:896-908
Wilson, Parker C; Lee, Mi-Hye; Appleton, Kathryn M et al. (2013) The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers. J Biol Chem 288:18872-84
Morinelli, Thomas A; Lee, Mi-Hye; Kendall, Ryan T et al. (2013) Angiotensin II activates NF-?B through AT1A receptor recruitment of ?-arrestin in cultured rat vascular smooth muscle cells. Am J Physiol Cell Physiol 304:C1176-86
Appleton, Kathryn M; Lee, Mi-Hye; Alele, Christian et al. (2013) Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity. Methods Enzymol 522:229-62
Morinelli, Thomas A; Kendall, Ryan T; Luttrell, Louis M et al. (2009) Angiotensin II-induced cyclooxygenase 2 expression in rat aorta vascular smooth muscle cells does not require heterotrimeric G protein activation. J Pharmacol Exp Ther 330:118-24